News|Articles|November 20, 2026

Rezatapopt Shows Durable Responses in TP53 Y220C-Mutated PROC

Fact checked by: Tim Cortese

Rezatapopt monotherapy yielded an ORR of 48% in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer.

The primary analysis of the phase 2 PYNNACLE trial (NCT04585750) showed that rezatapopt (PC14586) monotherapy produced an objective response rate (ORR) of 48% in patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation, according to a news release from the developer, PMV Pharmaceuticals.1 The results were shared as part of a late-breaking oral presentation at the 38th European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics. The company plans to submit a new drug application (NDA) in the first quarter of 2027.1

What did the primary analysis show in platinum-resistant/refractory ovarian cancer?

At a September 4, 2026, data cutoff, 65 patients with platinum-resistant/refractory ovarian cancer who had received prior standard of care were evaluable. By investigator assessment per RECISTv1.1, the ORR was 48% (n = 31/65), including 1 complete response and 30 partial responses. Median duration of response was 10.4 months, and the disease control rate was 83%. Responses occurred regardless of additional TP53 or other oncogenic alterations at baseline, and 45 of 50 patients with circulating tumor DNA data (90%) had a reduction of at least 50% in TP53 Y220C variant allele frequency within 3 to 6 weeks.

“Patients with platinum-resistant ovarian cancer who have progressed on standard therapies have few treatment options,” said Alison M. Schram, MD, medical oncologist at Memorial Sloan Kettering Cancer Center and a PYNNACLE investigator, in the press release.1 “In this heavily pretreated population, nearly half of patients with platinum-resistant/refractory ovarian cancer responded to rezatapopt, and those responses lasted a median of more than 10 months.”

What were the results across all tumor types, and how tolerable was rezatapopt?

In the overall efficacy population of 168 patients, the ORR was 36% (n = 61/168), with a median time to response of 1.3 months and a median duration of response of 8.1 months. By cohort, the ORR was 45% in ovarian cancer (n = 45/101), 45% in endometrial cancer (n = 5/11), 21% in lung cancer (n = 4/19), 17% in breast cancer (n = 3/18), and 21% in other solid tumors (n = 4/19). Among 180 patients in the safety population, most treatment-related adverse effects were grade 1 or 2, individual grade 3 events occurred in 7.2% or fewer of patients, and 11 patients (6%) discontinued because of them.

What was the design of PYNNACLE, and what comes next?

PYNNACLE is a phase 1/2 trial of rezatapopt at 2000 mg orally once daily in advanced solid tumors with a TP53 Y220C mutation. The registrational, single-arm phase 2 portion includes 5 cohorts (ovarian, lung, breast, endometrial, and other solid tumors) at approximately 70 sites. Eligible patients were 18 years or older, or 12 to 17 years with Safety Review Committee approval, with a locally advanced or metastatic solid tumor, 1 or more prior lines of therapy with progressive disease, an ECOG performance status of 0 or 1, adequate organ function, and measurable disease.2 The primary end point is ORR per RECIST version 1.1 by independent review in all cohorts and in the ovarian cohort.

Rezatapopt previously received fast track designation from the FDA for locally advanced or metastatic solid tumors with a p53 Y220C mutation and orphan drug designation for TP53 Y220C-positive ovarian, fallopian tube, and primary peritoneal cancers.1 Updated interim data showed an ORR of 46% (n = 35/76) in the ovarian cancer cohort at a May 14, 2026, cutoff,3 and an earlier interim analysis showed an ORR of 43% (n = 19/44) in ovarian cancer at an August 4, 2025, cutoff.4

“For patients who have endured multiple rounds of chemotherapy, rezatapopt has the potential to be a single-agent, chemotherapy-free, once-daily oral option they can take at home,” said Deepika Jalota, PharmD, chief development officer of PMV Pharma, in the press release.1 “We expect to submit our NDA for accelerated approval in the first quarter of 2027.”

References

  1. PMV Pharmaceuticals announces promising updated data from the PYNNACLE phase 2 pivotal trial of rezatapopt monotherapy in patients with TP53 Y220C-mutated advanced solid tumors. News release. PMV Pharmaceuticals, Inc. November 20, 2026. Accessed November 20, 2026. https://tinyurl.com/4nm3kn28
  2. The evaluation of PC14586 in patients with advanced solid tumors harboring a TP53 Y220C mutation (PYNNACLE). ClinicalTrials.gov. Updated October 2, 2026. Accessed November 20, 2026. https://tinyurl.com/5chshtyk
  3. PMV Pharmaceuticals announces updated promising rezatapopt monotherapy interim ovarian cancer data from PYNNACLE phase 2 pivotal trial. News release. PMV Pharmaceuticals, Inc. August 31, 2026. Accessed November 20, 2026. https://tinyurl.com/2yewchbn
  4. PMV Pharmaceuticals announces promising rezatapopt monotherapy interim data from PYNNACLE phase 2 trial across multiple solid tumors with a TP53 Y220C mutation. News release. PMV Pharmaceuticals, Inc. September 10, 2025. Accessed November 20, 2026. https://tinyurl.com/4uxnj92t

Related to this article